Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study EC Schwalbe, JC Lindsey, S Nakjang, S Crosier, AJ Smith, D Hicks, ... The Lancet Oncology 18 (7), 958-971, 2017 | 516 | 2017 |
Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes M Clarke, A Mackay, B Ismer, JC Pickles, RG Tatevossian, S Newman, ... Cancer discovery 10 (7), 942-963, 2020 | 217 | 2020 |
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease RM Hill, S Kuijper, JC Lindsey, K Petrie, EC Schwalbe, K Barker, ... Cancer cell 27 (1), 72-84, 2015 | 216 | 2015 |
Development and characterisation of a glutamate‐sensitive motor neurone cell line CJ Eggett, S Crosier, P Manning, MR Cookson, FM Menzies, CJ McNeil, ... Journal of neurochemistry 74 (5), 1895-1902, 2000 | 127 | 2000 |
Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity Y Grabovska, A Mackay, P O’Hare, S Crosier, M Finetti, EC Schwalbe, ... Nature communications 11 (1), 4324, 2020 | 99 | 2020 |
Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study RM Hill, S Richardson, EC Schwalbe, D Hicks, JC Lindsey, S Crosier, ... The Lancet Child & Adolescent Health 4 (12), 865-874, 2020 | 71 | 2020 |
Dual targeting of PDGFRα and FGFR1 displays synergistic efficacy in malignant rhabdoid tumors JP Wong, JR Todd, MA Finetti, F McCarthy, M Broncel, S Vyse, ... Cell reports 17 (5), 1265-1275, 2016 | 55 | 2016 |
A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines RE Culpin, SJ Proctor, B Angus, S Crosier, JJ Anderson, T Mainou-Fowler International journal of oncology 37 (2), 367-376, 2010 | 54 | 2010 |
Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse S Richardson, RM Hill, C Kui, JC Lindsey, Y Grabovksa, C Keeling, ... Neuro-oncology 24 (1), 153-165, 2022 | 38 | 2022 |
Infant high grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. Cancer Discov; 2020 M Clarke, A Mackay, B Ismer, JC Pickles, RG Tatevossian, S Newman, ... CD-19-1030.[Europe PMC free article][Abstract][CrossRef][Google Scholar] 10 …, 2020 | 35 | 2020 |
c-MYC is a radiosensitive locus in human breast cells MA Wade, NJ Sunter, SE Fordham, A Long, D Masic, LJ Russell, ... Oncogene 34 (38), 4985-4994, 2015 | 35 | 2015 |
Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar development D Williamson, EC Schwalbe, D Hicks, KA Aldinger, JC Lindsey, S Crosier, ... Cell reports 40 (5), 2022 | 34 | 2022 |
Minimal methylation classifier (MIMIC): A novel method for derivation and rapid diagnostic detection of disease-associated DNA methylation signatures EC Schwalbe, D Hicks, G Rafiee, M Bashton, H Gohlke, A Enshaei, ... Scientific reports 7 (1), 13421, 2017 | 34 | 2017 |
Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics JJ Anderson, S Fordham, L Overman, H Dignum, K Wood, SJ Proctor, ... International journal of oncology 35 (5), 961-971, 2009 | 30 | 2009 |
A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2 T Mainou-Fowler, LM Overman, H Dignum, K Wood, S Crosier, B Angus, ... International journal of oncology 32 (1), 59-68, 2008 | 19 | 2008 |
The proteomic landscape of soft tissue sarcomas J Burns, CP Wilding, L Krasny, X Zhu, M Chadha, YB Tam, H Ps, ... Nature Communications 14 (1), 3834, 2023 | 14 | 2023 |
The molecular landscape and associated clinical experience in infant medulloblastoma: prognostic significance of second‐generation subtypes D Hicks, G Rafiee, EC Schwalbe, CI Howell, JC Lindsey, RM Hill, ... Neuropathology and Applied Neurobiology 47 (2), 236-250, 2021 | 14 | 2021 |
Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnostics S Crosier, D Hicks, EC Schwalbe, D Williamson, S Leigh Nicholson, ... Neuropathology and Applied Neurobiology 47 (6), 736-747, 2021 | 9 | 2021 |
MDM2 RNA binding is blocked by novel monoclonal antibody h-MDM2-F4-14 JJ Anderson, C Challen, H Atkins, R Suaeyun, S Crosier, J Lunec International journal of oncology 31 (3), 545-555, 2007 | 8 | 2007 |
Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification J Goddard, J Castle, E Southworth, A Fletcher, S Crosier, ... Acta neuropathologica 145 (5), 651-666, 2023 | 6 | 2023 |